All In Biotech

Drug Trial Radar · NCT05421598

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma

Last checked: Nov 19, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Jun 30, 2022

Primary completion

Oct 11, 2024

Study completion Mar 20, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment. The purpose of this study was to assess the efficacy, safety, and tolerability of add-on therapy with amlitelimab in adult participants with moderate-to-severe asthma. Study details include: * The study duration (per participant) was up to approximately 76 weeks for participants not going into LTS study and will be up to approximately 64 weeks for participants going into LTS study. * The randomized treatment duration was up to approximately 60 weeks. * The scheduled number of visits was 13.

Conditions

  • Asthma

Interventions

  • AmlitelimabDrug

    Injection solution Subcutaneous injection

  • PlaceboDrug

    Injection solution Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Rate of Severe Asthma Exacerbation Events Over 48 WeeksTime frame: Baseline (Day 1) to Week 48

Locations

113 sites in 14 countries. Site status is shown where the registry gives one.

  • University of California San Diego Health Site Number : 8400026

    La Jolla, California

  • California Allergy and Asthma Medical Group, Inc. Site Number : 8400002

    Los Angeles, California

  • Allergy Asthma Associates of Santa Clara Valley Site Number : 8400019

    San Jose, California

  • Bensch Clinical Research LLC Site Number : 8400004

    Stockton, California

  • Allianz Research Institute Site Number : 8400023

    Westminster, California

  • Helix Biomedics, LLC Site Number : 8400029

    Boynton Beach, Florida

  • Renaissance Research and Medical Group, Inc Site Number : 8400030

    Cape Coral, Florida

  • Beautiful Minds Clinical Research Center Site Number : 8400027

    Cutler Bay, Florida

  • Reliable Clinical Research, LLC Site Number : 8400020

    Hialeah, Florida

  • Savin Medical Group, LLC Site Number : 8400015

    Miami, Florida

  • Pines Care Research Center LLC Site Number : 8400028

    Pembroke Pines, Florida

  • Treasure Valley Medical Research Site Number : 8400031

    Boise, Idaho

  • The South Bend Clinic, LLC Site Number : 8400033

    South Bend, Indiana

  • University of Kansas Medical Center Site Number : 8400016

    Kansas City, Kansas

  • Johns Hopkins University School of Medicine Site Number : 8400012

    Baltimore, Maryland

  • Headlands Research Detroit Site Number : 8400032

    Southfield, Michigan

  • Henderson Clinical Trials Site Number : 8400037

    Henderson, Nevada

  • Asthma and Allergy Center Site Number : 8400005

    Toledo, Ohio

  • OK Clinical Research, LLC Site Number : 8400001

    Edmond, Oklahoma

  • Allergy, Asthma and Clinical Research Center Site Number : 8400035

    Oklahoma City, Oklahoma

  • TTS Research Site Number : 8400011

    Boerne, Texas

  • Investigational Site Number : 0320004

    Buenos Aires, Argentina

  • Investigational Site Number : 0320003

    Ciudad Autonoma Buenos Aires, Argentina

  • Investigational Site Number : 0320001

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320002

    CABA, Buenos Aires, Argentina

  • Investigational Site Number : 0320008

    La Plata, Buenos Aires, Argentina

  • Investigational Site Number : 0320009

    Buenos Aires, Buenos Aires F.D., Argentina

  • Investigational Site Number : 0320006

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320007

    Rosario, Santa Fe Province, Argentina

  • Investigational Site Number : 0320005

    Rosario, Santa Fe Province, Argentina

  • CEDOES - Centro de Diagnostico e Pesquisa de Osteoporose do ES Site Number : 0760002

    Vitória, Espírito Santo, Brazil

  • Proar Site Number : 0760004

    Salvador, Estado de Bahia, Brazil

  • Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760010

    Natal, Rio Grande do Norte, Brazil

  • Instituto Mederi de Pesquisa e Saude Site Number : 0760001

    Passo Fundo, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericordia de Porto Alegre Site Number : 0760007

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Sao Lucas da PUCRS Site Number : 0760006

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital das Clinicas de Sao Paulo Site Number : 0760008

    São Paulo, São Paulo, Brazil

  • Clinica de Alergia Martti Antila Site Number : 0760003

    Sorocaba, São Paulo, Brazil

  • Investigational Site Number : 1240003

    Québec, Canada

  • Investigational Site Number : 1240006

    Brampton, Ontario, Canada

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.